Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Allograft rejection 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
2 Allograft rejection 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
3 Allograft rejection 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
4 Asthma 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
5 Asthma 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
6 Asthma 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
7 Autoimmune thyroid disease 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
8 Autoimmune thyroid disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
9 Autoimmune thyroid disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
10 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
11 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
12 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
13 Cytokine-cytokine receptor interaction 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
14 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
15 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
16 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
17 Hematopoietic cell lineage 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
18 Hematopoietic cell lineage 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
19 Hematopoietic cell lineage 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
20 Hematopoietic cell lineage 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
21 IL-17 signaling pathway 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
22 IL-17 signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
23 IL-17 signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
24 Inflammatory bowel disease 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
25 Inflammatory bowel disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
26 Inflammatory bowel disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
27 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
28 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
29 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
30 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
31 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
32 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
33 JAK-STAT signaling pathway 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
34 Pathways in cancer 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
35 Pathways in cancer 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
36 Pathways in cancer 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
37 Pathways in cancer 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
38 T cell receptor signaling pathway 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
39 T cell receptor signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
40 T cell receptor signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
41 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
42 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
43 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬

先頭へ